Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enhertu Poised To Rewrite The Standard Of Care After ESMO

Executive Summary

AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.

You may also be interested in...



Zymeworks Rejects ‘Opportunistic’ Investor Takeover Bid

Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news to help fight off the bid.

AstraZeneca/Daiichi's Enhertu Expansion Strategy Progresses With New Approval

Enhertu secured US FDA approval as a second-line treatment in HER2-positive breast cancer, where it is poised to become the new standard of care.

AstraZeneca and Daiichi Sankyo’s Enhertu Eyes 50% Of Breast Cancer Market Following HER2-Low Data

Transformative product is the first to demonstrate benefit in HER2-low metastatic breast cancer, broadening its market potential to nearly half of all breast cancers.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel